{"title":"Lansoprazole/β-Cyclodextrin-Based Metal-Organic Frameworks: Development, Characterization, and Anti-Ulcer Activity Evaluation on Rats.","authors":"Bader B Alsulays","doi":"10.2174/0115672018449532260409081159","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gastric ulcers are among the most common diseases worldwide, affecting individuals of all ages and genders. Lansoprazole (LNS) is one of the first-choice treatments for ulcers. In this study, β-Cyclodextrin-based metal-organic frameworks (β-CD-MOFs), which have recently attracted attention for biomedical applications, were used as carriers for LNS to enhance its physicochemical properties.</p><p><strong>Methods: </strong>β-CD-MOF crystals were prepared, and LNS was successfully loaded into the crystals in the presence of MgO. Pure LNS and the formulation were characterized using Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier-Transform Infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and in vitro release studies. The anti-ulcer activity was evaluated in male Wistar albino rats.</p><p><strong>Results: </strong>Dissolution studies revealed that approximately 90% of LNS was released from the formulation within 60 minutes, and the formulation's color remained unchanged after exposure to light. The formulation demonstrated a significant reduction in mucosal erythema and mucosal surface lesions, as well as a higher percentage of ulcer index inhibition.</p><p><strong>Discussion: </strong>Loading of LNS into β-CD-MOF enhanced its release and photostability. In vivo studies suggest that the formulation has a potent anti-ulcerogenic capability comparable to that of LNS.</p><p><strong>Conclusion: </strong>β-CD-MOF, a promising carrier in drug delivery, improves the properties of LNS and further enhances its anti-ulcer activity.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018449532260409081159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Gastric ulcers are among the most common diseases worldwide, affecting individuals of all ages and genders. Lansoprazole (LNS) is one of the first-choice treatments for ulcers. In this study, β-Cyclodextrin-based metal-organic frameworks (β-CD-MOFs), which have recently attracted attention for biomedical applications, were used as carriers for LNS to enhance its physicochemical properties.
Methods: β-CD-MOF crystals were prepared, and LNS was successfully loaded into the crystals in the presence of MgO. Pure LNS and the formulation were characterized using Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier-Transform Infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and in vitro release studies. The anti-ulcer activity was evaluated in male Wistar albino rats.
Results: Dissolution studies revealed that approximately 90% of LNS was released from the formulation within 60 minutes, and the formulation's color remained unchanged after exposure to light. The formulation demonstrated a significant reduction in mucosal erythema and mucosal surface lesions, as well as a higher percentage of ulcer index inhibition.
Discussion: Loading of LNS into β-CD-MOF enhanced its release and photostability. In vivo studies suggest that the formulation has a potent anti-ulcerogenic capability comparable to that of LNS.
Conclusion: β-CD-MOF, a promising carrier in drug delivery, improves the properties of LNS and further enhances its anti-ulcer activity.